SmarTrend(R) News Watch: Enzon Pharmaceuticals Reports Mixed Results
ENZN | Quote | Chart | News | PowerRating -- Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) reported a Q4 loss of $500K, or $0.01 per fully diluted share, beating analyst estimates for a loss of $0.16 per share. Net revenues for the quarter were flat year-over-year at $48.1 million, short of the analyst consensus estimate for $50.4 million. The Company expects to spend approximately 40% of the $80 to $90 million R&D budget on the next-generation Adagen and Oncaspar programs and remain operating cash flow neutral. Jeffrey H. Buchalter, chairman and chief executive officer of the Company, said "Enzon continues to improve the fundamentals of the Company, as seen in the improvement of the balance sheet and operational efficiencies."
newsdesk@comtex.com
SmarTrend scans over 5,000 stocks daily and alerts you when a change in trend is identified. Visit http://www.mysmartrend.com for more details.
Want to license news for your website? Visit http://www.comtex.com to discover how you can get customized news relevant to your site.
For full details on Enzon Pharmaceuticals Inc (ENZN) ENZN. Enzon Pharmaceuticals Inc (ENZN) has Short Term PowerRatings at TradingMarkets. Details on Enzon Pharmaceuticals Inc (ENZN) Short Term PowerRatings is available at This Link.
- CORRECTING and REPLACING Enzon to Release Fourth Quarter 2009 Earnings on Wednesday, February 17, 2010; Conference Call and Webc - 02/09/10
- Enzon to Release Fourth Quarter 2009 Earnings on Wednesday, February 17, 2010; Conference Call and Webcast to Follow - 02/09/10
- Enzon Pharmaceuticals: The Trend Continues Down (ENZN) - 02/05/10
- SmarTrend's Candlestick Scanner Detects Bearish Engulfing Pattern for Enzon Pharmaceuticals (ENZN) - 02/02/10
- Enzon Pharmaceuticals sells specialty pharmaceutical business to Sigma-Tau - 02/01/10
- More News >>


